Peptide-Mediated Regulation of Allergic Diseases

  • Charlotte Hetzel
  • Gerard F. Hoyne
  • Nanna M. Kristensen
  • Timothy Bourne
  • Daphne Tsitoura
  • Jonathan R. Lamb


Allergic disorders such as asthma and atopic dermatitis are the result of inappropriate immune responses to environmental allergens, particularly those derived from house dust mites, pollens, animal dander, fungal spores, insect venom and certain foods. An estimated 10 to 20% of the population of developed countries suffer from allergies, resulting in significant impairment of their quality of life.1 The allergic response is characterized by an over production of specific IgE antibody and the activation and infiltration of eosinophils, basophils and mast cells which release a spectrum of inflammatory mediators.2 Traditional allergen immunotherapy, which involves a series of injections of allergen extract, has proved beneficial in a limited number of disorders, notably bee venom allergy and allergic rhinitis due to grass and tree pollens and ragweed.3 However, the mechanisms of immunotherapy are poorly understood and, particularly in the case of inhalant allergens, are of limited efficacy, with variable clinical outcomes.4 There remains a need for safe and effective strategies of allergy therapy and a clearer understanding of the mechanisms involved.


Major Histocompatibility Complex Experimental Autoimmune Encephalomyelitis Major Histocompatibility Complex Class Cell Clone Allergic Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Statistics of Allergic Diseases and Immunology. Milwaukee: American Academy of Allergy and Immunology, 1992.Google Scholar
  2. 2.
    Ishizaka K, Ishizaka T. Allergy. In: Paul WE, ed. Fundamental Immunology. 2nd ed. New York: Raven Press, 1989: 867–888Google Scholar
  3. 3.
    Bousquet J, Michel FB. New prospects for immunotherapy in asthma. In: T-lymphocyte and Inflammatory Cell Research in Asthma. Academic Press, 1993: 55–83.Google Scholar
  4. 4.
    Ewan PW. Allergen immunotherapy. Curr Opin Immunol 1989; 1: 672–678.Google Scholar
  5. 5.
    Vercelli D, Jabara HH, Arai K et al. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J Exp Med 1989; 169: 1295–1307.Google Scholar
  6. 6.
    Snapper CM, Paul WE. Interferon-y and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236: 944–947.Google Scholar
  7. 7.
    Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989; 73: 1504–1512.Google Scholar
  8. 8.
    Mosmann TR, Schumacher JH, Street NF et al. Diversity of cytokine synthesis and the function of mouse CD4’ T cells. Immunol Rev 1991; I23: 209–229.Google Scholar
  9. 9.
    Street NF, Schumacher JH, Fong TAT et al. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol 1990; 144: 1629–1639.Google Scholar
  10. 10.
    Del Prete GF, De Carli M, Mastromauro C et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (Type 1 T helper or Type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346–350.Google Scholar
  11. 11.
    Wierenga EA, Snoek M, Bos JD et al. Comparison of diversity and function of house dust mite-specific T lymphocyte clones from atopic and non-atopic donors. Eur J Immunol 1990; 20: 1519–1526.Google Scholar
  12. 12.
    Romagnani S. Human Thl and Th2 subsets: doubt no more. Immunol Today 1991; 12 (8): 256–257.Google Scholar
  13. 13.
    Kapsenberg ML, Wierenga EA, Bos JA et al. Functional subsets of allergen-reactive human CD4’ T cells. Immunol Today 1991; 12 (11): 392–395.Google Scholar
  14. 14.
    Mahanty S, King CL, Kumaraswami V et al. IL-4- and IL-5-secreting lymphocyte populations are preferentially stimulated by parasite-derived antigens in human tissue invasive nematode infections. J Immunol 1993; 151: 3704–3711.Google Scholar
  15. 15.
    Field EH, Noelle RJ, Rouse T et al. Evidence for excessive Th2 CD4’ subset activity in vivo. J Immunol 1993; 151: 48–59.Google Scholar
  16. 16.
    Lesourd B, Paupe J, Thiollet M et al. Hymenoptera venom immunotherapy. I. Induction of T cell-mediated immunity by honeybee venom immunotherapy: relationships with specific antibody responses. J Allergy Clin Immunol 1989; 83: 563–571.Google Scholar
  17. 17.
    Einarsson R, Dreborg S, Hammarstrom L et al. Monitoring of mite Dermatophagoides farinae allergen-specific IgG and IgG subclass distribution in patients on immunotherapy. Allergy 1992; 47: 76–82.Google Scholar
  18. 18.
    Pastorello EA, Pravettoni V, Incorvaia C et al. Clinical and immunological effects of immunotherapy with alum-adsorbed grass allergoid in grasspollen-induced hay fever. Allergy 1992; 47: 281–290.Google Scholar
  19. 19.
    Sparholt SH, Olsen OT, Schou C. The allergen specific B cell response during immunotherapy. Clin Exp Allergy 1992; 22 (6): 648–653.Google Scholar
  20. 20.
    Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy 1993; 71 (5): 461–469.Google Scholar
  21. 21.
    Wilson AB, Deighton J, Lachmann PJ et al. A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom. Allergy 1994; 49: 272–280.Google Scholar
  22. 22.
    Gascan H, Gauchat J-F, Roncarolo M-G et al. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by IL-4 and a signal provided by activated CD4’ T cell clones. J Exp Med 1991; 173: 747–754.Google Scholar
  23. 23.
    Mazanec MB, Nedrud JG, Kaetzel CS et al. A three-tiered view of the role of IgA in mucosal defence. Immunol Today 1993; 14 (9): 430–435.Google Scholar
  24. 24.
    Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14 (1): 15–17.Google Scholar
  25. 25.
    Defrance T, Vanbervliet B, Briere F et al. Interleukin 10 and transforming growth factor ß cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med 1992; 175: 671–682.Google Scholar
  26. 26.
    Vercelli D, Jabara HH, Arai K-I et al. Endogenous interleukin-6 plays an obligatory role in interleukin 4 dependent human IgE synthesis. Eur J Immunol 1989; 19: 1419–1424.Google Scholar
  27. 27.
    Kay AB, Ying S, Varney VA et al. Messenger RNA expression of the cytokine gene cluster, interleukin-3 (IL-3), IL-4, IL-5, and granulocyte/ macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775–778.Google Scholar
  28. 28.
    Varney VA, Hamid Q, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 644–651.Google Scholar
  29. 29.
    Secrist H, Chelen CJ, Wen Y et al. Allergen immunotherapy decreases interleukin 4 production in CD4’ T cells from allergic individuals. J Exp Med 1993; 178: 2123–2130.Google Scholar
  30. 30.
    O’Hehir RE, Bal V, Quint D et al. An in vitro model of allergen dependent IgE synthesis by human B cells: comparison of the response of an atopic and non-atopic individual to Dermatophagoides spp. Immunol 1989; 66: 499.Google Scholar
  31. 31.
    Briner TJ, Kuo M-C, Keating KM et al. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA 1993; 90: 7608–7612.Google Scholar
  32. 32.
    Dintzis HM, Dintzis RZ. Profound specific suppression by antigen of persistent IgM, IgG, and IgE antibody production. Proc Natl Acad Sci USA 1992; 89: 1113–1117.Google Scholar
  33. 33.
    Bradley LM, Croft M, Swain SL. T cell memory: new perspectives. Immunol Today 1993; 14: 197–199.Google Scholar
  34. 34.
    Röcken M, Muller KM, Saurat J-H et al. Central role for TCR/CD3 ligation in the differentiation of CD4’ T cells toward a Thl or Th2 functional phenotype. J Immunol 1992; 148: 47–54.Google Scholar
  35. 35.
    Panina-Bordignon P, Tan A, Termijtelen A et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989; 19: 2237–2242.Google Scholar
  36. 36.
    Sette A, Buus S, Colon S et al. Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol 1989; 142: 35–40.Google Scholar
  37. 37.
    Busch R, Strang G, Howland K et al. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Infect Immun 1990; 2: 443–451.Google Scholar
  38. 38.
    Rothbard JB, Busch R, Bal V et al. Reversal of HLA restriction by a point mutation in an antigenic peptide. Infect Immun 1989; 1: 487–495.Google Scholar
  39. 39.
    O’Hehir RE, Busch R, Rothbard JB et al. An in vitro model of peptide-mediated immunomodulation of the human T cell response to Dermatophagoides spp. (house dust mite). J Allergy Clin Immunol 1991; 87 (6): 1120–1127.Google Scholar
  40. 40.
    Lamont AG, Sette A, Fujinami R et al. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with a high affinity for IAS molecules. J Immunol 1990; 145: 1687–1693.Google Scholar
  41. 41.
    Gautam AM, Pearson CI, Sinha AA et al. Inhibition of experimental autoimmune encephalomyelitis by a non-immunogenic non-self peptide that binds to I-A’. J Immunol 1992; 148: 3049–3054.Google Scholar
  42. 42.
    Oehir RE, Hoyne GF, Thomas WR et al. House dust mite allergy: from T cell epitopes to immunotherapy. Eur J Clin Invest 1993; 23: 763–772.Google Scholar
  43. 43.
    Marsh DG, Friedhoff LR. HLA genes determining susceptibility to allergy. In: Kraft D, Sehon A, eds. Molecular Biology and Immunology of Allergens. CRC Press, 1993: 1–9.Google Scholar
  44. 44.
    O’Hehir RE, Mach B, Berte C et al. Direct evidence for a functional role of HLA-DRB1 and -DRB3 gene products in the recognition of Dermatophagoides spp. (house dust mite) by helper T lymphocytes. Infect Immun 1990; 2 (9): 885–892.Google Scholar
  45. 45.
    Marsh DG, Zwollo P, Huang SK et al. Molecular studies of human immune response to allergens. Cold Harbour Symp Quant Biol 1989; 54: 459.Google Scholar
  46. 46.
    Higgins JA, Lamb JR, Marsh DG et al. Peptide-induced nonresponsiveness of HLA-DP restricted human T cells reactive with Dermatophagoides spp (house dust mite). J Allergy Clin Immunol 1992; 90 (5): 749–756.Google Scholar
  47. 47.
    Verhoef A, Higgins JA, Thorpe CJ et al. Clonal analysis of the atopic immune response to the group 2 allergen of Dermatophagoides spp: identification of HLA-DR and -DQ restricted T cell epitopes. Infect Immun 1993; 5 (12): 1589–1597.Google Scholar
  48. 48.
    Adorini L. Tolerance induction in mature T cells. The Immunologist 1993; 1: 185–190.Google Scholar
  49. 49.
    Hammerling GJ, Schönrich G, Momburg F et al. Non-deletion mechanisms of peripheral and central tolerance: Studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol Rev 1991; 122: 47–67.Google Scholar
  50. 50.
    Raff MC. Social controls on cell survival and cell death. Nature (London) 1992; 356: 397–400.Google Scholar
  51. 51.
    Moskophidis D, Lechner F, Pircher H et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector cells. Nature (London) 1993; 362: 758–761.Google Scholar
  52. 52.
    Jenkins MK, Schwartz RH. Antigen presentation by chemically-modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987; 165: 302–319.Google Scholar
  53. 53.
    Sloan-Lancaster S, Evavold BD, Allen PM. Induction of T cell anergy by altered T cell-receptor ligand on live antigen-presenting cells. Nature (London) 1993; 363: 156–159.Google Scholar
  54. 54.
    Schönrich G, Kalinke U, Momburg F et al. Downregulation of T cell receptors on self-reactive cells as a novel mechanism for extrathymic tolerance induction. Cell 1991; 65: 292.Google Scholar
  55. 55.
    Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol 1989; 7: 445–481.Google Scholar
  56. 56.
    Freedman AS, Freeman GJ, Horowitz JC et al. B7, a B cell restricted antigen which identifies pre-activated B cells. J Immunol 1987; 137: 3260–3267.Google Scholar
  57. 57.
    Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993; 11: 191–212.Google Scholar
  58. 58.
    Azuma M, Ito D, Yagita H et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature (London) 1993; 366: 76–79.Google Scholar
  59. 59.
    Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349–1356.Google Scholar
  60. 60.
    Lamb JR, Skidmore BJ, Green N et al. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983; 157: 1434–1447.Google Scholar
  61. 61.
    Matis LA, Glimcher LH, Paul WE et al. Magnitude of the response of histocompatibility-restricted T cell clones is a function of the product of the concentrations of antigen and Ia molecules. Proc Natl Acad Sci USA 1983; 80: 6019–6023.Google Scholar
  62. 62.
    Suzuki G, Kawase Y, Koyasu S et al. Antigen-induced suppression of the proliferative response of T cell clones. J Immunol 1988; 140: 1359–1365.Google Scholar
  63. 63.
    Nau GJ, Moldwin RL, Lancki DW et al. Inhibition of IL-2-driven proliferation of murine T lymphocyte clones by supraoptimal levels of immobilised anti-T cell receptor monoclonal antibody. J Immunol 1987; 139: 114–122.Google Scholar
  64. 64.
    Sloan-Lancaster J, Allen PM. Significance of T cell stimulation by altered peptide ligands in T cell biology. Curr Opin Immunol 1995; 7: 103–109.Google Scholar
  65. 65.
    O’Hehir RE, Yssel H, Verma S et al. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol 1991; 3 (8): 819–826.Google Scholar
  66. 66.
    O’Hehir RE, Lamb JR. Induction of specific clonal anergy in human T lymphocytes by Staphylococcus aureus enterotoxins. Proc Natl Acad Sci USA 1990; 87: 8884–8888.Google Scholar
  67. 67.
    O’Hehir RE, Aguilar BA, Schmidt TJ et al. Functional inactivation of Dermatophagoides spp. (house dust mite) reactive T cell clones. Clin Exp Allergy 1991; 21: 209–215.Google Scholar
  68. 68.
    Lake RA, O’Hehir RE, Verhoef A et al. CD28 mRNA rapidly decays when activated T cells are functionally anergised with specific peptide. Int Immunol 1993; 5 (5): 461–466.Google Scholar
  69. 69.
    Arnold B, Schonrich G, Hammerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993; 14: 12–14.Google Scholar
  70. 70.
    Jenkins MK, Chen C, Jung G et al. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144: 16–22.Google Scholar
  71. 71.
    Williams ME, Lichtman AH, Abbas AK. Anti-CD3 antibody induces unresponsiveness to IL 2 in Thl clones but not in Th2 clones. J Immunol 1990; 144: 1208–1214.Google Scholar
  72. 72.
    Kang S-M, Beverly B, Tran A-C et al. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 1993; 257: 1134–1138.Google Scholar
  73. 73.
    Cho EA, Riley MP, Sillman AL et al. Altered tyrosine kinase phosphorylation in anergic Th1 cells. J Immunol 1993; 151: 20–28.Google Scholar
  74. 74.
    Gilbert KM, Hoang KD, Weigle WO. Th1 and Th2 clones differ in their response to a tolerogenic signal. J Immunol 1990; 144: 2063–2071.Google Scholar
  75. 75.
    Hoyne GF, O’Hehir RE, Wraith DC et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitised mice. J Exp Med 1993; 178: 1783–1788.Google Scholar
  76. 76.
    Hoyne GF, Callow MG, Kuhlman J et al. T cell lymphokine response to orally administered proteins during priming and unresponsiveness. Immunol 1993; 78: 534–540.Google Scholar
  77. 77.
    Burnstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-y-producing (Th1) cells. J Immunol 1992; 148: 3687–3691.Google Scholar
  78. 78.
    Peterson JD, Karpus WJ, Clatch RJ et al. Split tolerance of Thl and Th2 cells in tolerance to Theiler’s murine encephalomyelitis virus. Eur J Immunol 1993; 23: 46–55.Google Scholar
  79. 79.
    Gieni RS, Yang X, HayGlass KT. Allergen-specific modulation of cytokine synthesis patterns and IgE responses in vivo with chemically modified allergen. J Immunol 1993; 150: 302–316.Google Scholar
  80. 80.
    de Wit D, Van Mechelen M, Ryelandt M et al. The injection of deaggregated gamma globulins in adult mice induces antigen specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J Exp Med 1992; 175: 9–14.Google Scholar
  81. 81.
    Romball CG, Weigle WO. In vivo induction of tolerance in murine CD4* cell subsets. J Exp Med 1993; 178: 1637–1644.Google Scholar
  82. 82.
    Holt PG, Batty JE, Turner KJ. Inhibition of specific IgE responses in mice by pre-exposure to inhaled antigen. Immunol 1981; 42: 409–417.Google Scholar
  83. 83.
    Rogers BL, Bond JF, Craig SJ et al. Potential therapeutic recombinant proteins comprised of peptides containing recombinant T cell epitopes. Molec Immunol 1994; 313: 9553–9663.Google Scholar
  84. 84.
    Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321–1324.Google Scholar
  85. 85.
    Miller A, Lider O, Robinson AB et al. Suppressor T cells generated by oral tolerisation to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89: 421–425.Google Scholar
  86. 86.
    Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Infect Immun 1993; 5 (9): 1159–1165.Google Scholar
  87. 87.
    Holt PG, Oliver J, Bilyk N et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993; 177: 397–407.Google Scholar
  88. 88.
    Sedgwick JD, Holt PG. Induction of IgE-secreting cells and IgE isotype specific suppressor T cells in the respiratory lymph nodes of rats in response to antigen inhalation. Cell Immunol 1985; 56: 182–194.Google Scholar
  89. 89.
    McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8* T cell-mediated but MHC class II-restricted CD4* T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993; 178: 889–899.Google Scholar
  90. 90.
    McMenamin C, Pimm C, McKersey M et al. Regulation of IgE responses to inhaled antigens in mice by antigen-specific yS T cells. Science 1994; 265: 1869–1871.Google Scholar
  91. 91.
    Sercarz E, Lehmann PV, Ametani A et al. Dominance and crypticity of T cell antigenic determinants. Ann Rev Immunol 1993; 11: 729–766.Google Scholar
  92. 92.
    Kearney ER, Pape KA, Loh DY et al. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1994; 1: 327–339.Google Scholar
  93. 93.
    Hoyne GF, Hetzel C, Askonas BA et al. Intranasal administration of a peptide derived from house dust mite induces a transient phase of activation of CD4’ T cells prior to the development of non-responsiveness. Submitted to International Immunol.Google Scholar
  94. 94.
    Reiner SL, Locksley RM. The worm and the protozoa: Stereotyped responses or distinct antigens. Parasitol Today 1993; 9 (7): 258–260.Google Scholar
  95. 95.
    Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4* T cells. Ann Rev Immunol 1994; 12: 635–673.Google Scholar
  96. 96.
    Hsieh C-S, Heimberger AB, Gold JS et al. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an aß T cell-receptor transgenic system. Proc Natl Acad Sci USA 1992; 89: 6065–6069.Google Scholar
  97. 97.
    Seder RA, Paul WE, Davis MM et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4* T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091–1098.Google Scholar
  98. 98.
    Schmitz J, Assenmacher M, Radbruch A. Regulation of T helper cell cytokine expression: functional dichotomy of antigen-presenting cells. Eur J Immunol 1993; 23: 191–199.Google Scholar
  99. 99.
    Gajewski TF, Pinnas M, Wong T et al. Murine Thl and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J Immunol 1991; 146: 1750–1758.Google Scholar
  100. 100.
    Kenney JS, Hughes BW, Masada MP et al. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Imm Methods 1989; 121: 157–166.Google Scholar
  101. 101.
    Kuchroo VK, Das MP, Brown JA et al. B7–1 and B7–2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways:application to autoimmune disease therapy. Cell 1995; 80: 707–718.Google Scholar
  102. 102.
    Shanafelt M-C, Soderberg C, Allsup A et al. Costimulatory signals can selectively modulate cytokine production by subsets of CD4* T cells. J Immunol 1995; 154: 1684–1690.Google Scholar
  103. 103.
    Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 1993; 14 (7): 335–338.Google Scholar
  104. 104.
    O’Garra A, Macatonia SE, Hsieh C-S et al. Regulatory role of IL-4 and other cytokines in T helper cell development in an aß-TCR transgenic mouse system. Res In Immunol 1993; 144 (8): 620–625.Google Scholar
  105. 105.
    Soloway P, Fish S, Passmore H et al. Regulation of the immune response to peptide antigens: Differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype. J Exp Med 1991; 174: 847–858.Google Scholar
  106. 106.
    Murray JS, Madri J, Pasqualini T et al. Functional CD4 T cell subset interplay in an intact immune system. J Immunol 1993; 150: 4270–4276.Google Scholar
  107. 107.
    Freeman GJ, Boussiotis VA, Anumanthan A et al. B7–1 and B7–2 do not deliver identical costimulatory signals, since B7–2 but not B7–1 preferentially costimulates the initial production of IL-4. Immunity 1995; 2: 523–532.Google Scholar
  108. 108.
    Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Ann Rev Immunol 1992; 10: 385–409.Google Scholar
  109. 109.
    Heinzel FP, Schoenhaut DS, Rerko RM et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177: 1505–1509.Google Scholar
  110. 110.
    Sypek JP, Chung CL, Mayor SEH et al. Resolution of cutaneous Leishmaniasis: Interleukin 12 initiates a protective T helper type 1 response. J Exp Med 1993; 177: 1797–1802.Google Scholar
  111. 111.
    Manetti R, Gerosa F, Giudizi M-G et al. Interleukin 12 induces stable priming for interferon y (IFN-y) production during differentiation of human T helper (Th) clones and transient IFN-y production in established Th2 cell clones. J Exp Med 1994; 179: 1273–1283.Google Scholar
  112. 112.
    Li JT, Yunginger J, Reed CE et al. Recombinant interferon-gamma in the treatment of allergic rhinitis. J Allergy Clin Immunol 1989; 83: 307.Google Scholar
  113. 113.
    Racioppi L, Ronchese F, Matis LA et al. Peptide-major histocompatibility complex class II complexes with mixed agonist-antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signalling. J Exp Med 1993; 177: 1047–1060.Google Scholar
  114. 114.
    Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991; 252: 1308–1310.Google Scholar
  115. 115.
    Sloan-Lancaster J, Shaw AS, Rothbard JB et al. Partial T cell signaling: altered phospho-and lack of Zap70 recruitment in APL-induced T cell anergy. Cell 1994; 79: 913–922.Google Scholar
  116. 116.
    Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 1994; 180: 1195–1205.Google Scholar
  117. 117.
    Lamb JR, Higgins JA, Hetzel C et al. The effects of changes at peptide residues contacting MHC class II or TCR on antigen recognition and human THO cell effector function. Immunol 1995 (in press)Google Scholar
  118. 118.
    Windhagen A, Scholz C, Hollsberg P et al. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2: 373–380.Google Scholar
  119. 119.
    Renz H, Saloga J, Bradley KL et al. Specific Vß T cell subsets mediate the immediate hypersensitivity response to ragweed allergen. J Immunol 1993; 151: 1907–1917.Google Scholar
  120. 120.
    Pfeiffer C, Stein J, Southwood S et al. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995; 181: 1569–1574.Google Scholar
  121. 121.
    Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature (London) 1991; 351: 456–460.Google Scholar
  122. 122.
    Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature (London) 1991; 351: 479–482.Google Scholar
  123. 123.
    Stover CK, Bansal GP, Hanson MS et al. Protective immunity elicited by recombinant Bacille-Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: A candidate Lyme disease vaccine. J Exp Med 1993; 178: 197–209.Google Scholar
  124. 124.
    Parronchi P, Macchia D, Piccinni M-P et al. Allergen-and bacterial antigen-specific T cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 1991; 88: 4538–4542.Google Scholar
  125. 125.
    Gheorghiu M, Lagranderie MRR, Gicquel BME et al. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect Immun 1994; 62 (10): 4287–4295.Google Scholar
  126. 126.
    Xiang Z, Ertl HCJ. Manipulation of the immune response to a plasmidencoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129–135.Google Scholar
  127. 127.
    Fynan EF, Webster RG, Fuller DH et al. DNA vaccines: protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 1993; 90: 11478–11482.Google Scholar
  128. 128.
    Kristensen NM, Hoyne GF, Hayball JD et al. Induction of T cell responses to the invariant chain-derived CLIP peptide in mice immunised with the group I allergen of house dust mite. Immunity (submitted).Google Scholar

Copyright information

© R.G. Landes Company 1996

Authors and Affiliations

  • Charlotte Hetzel
  • Gerard F. Hoyne
  • Nanna M. Kristensen
  • Timothy Bourne
  • Daphne Tsitoura
  • Jonathan R. Lamb

There are no affiliations available

Personalised recommendations